Cargando…

Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care

[Image: see text] Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient’s clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Saeromi, Singh, Naveen K., Gribkoff, Valentin K., Hall, Drew A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631757/
https://www.ncbi.nlm.nih.gov/pubmed/36340178
http://dx.doi.org/10.1021/acsomega.2c04865
_version_ 1784823885984694272
author Chung, Saeromi
Singh, Naveen K.
Gribkoff, Valentin K.
Hall, Drew A.
author_facet Chung, Saeromi
Singh, Naveen K.
Gribkoff, Valentin K.
Hall, Drew A.
author_sort Chung, Saeromi
collection PubMed
description [Image: see text] Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient’s clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly personalized manner. We report an electrochemical conformation-changing aptasensor with two assay formats: a 30 min assay for routine monitoring and a 5 min assay for rapid emergency testing. To enable “sample-to-answer” testing, a de novo CBZ aptamer (K(d) < 12 nM) with conformational switching due to a G-quadruplex motif was labeled with methylene blue and immobilized on a gold electrode. The electrode fabrication and detection conditions were optimized using electrochemical techniques and visualized by atomic force microscopy (AFM). The aptasensor performance, including reproducibility, stability, and interference, was characterized using electrochemical impedance spectroscopy and voltammetry techniques. The aptasensor exhibited a wide dynamic range in buffer (10 nM to 100 μM) with limits of detection of 1.25 and 1.82 nM for the 5 and 30 min assays, respectively. The clinical applicability is demonstrated by detecting CBZ in finger prick blood samples (<50 μL). The proposed assays provide a promising method to enable point-of-care monitoring for timely personalized CBZ dosing.
format Online
Article
Text
id pubmed-9631757
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-96317572022-11-04 Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care Chung, Saeromi Singh, Naveen K. Gribkoff, Valentin K. Hall, Drew A. ACS Omega [Image: see text] Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient’s clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly personalized manner. We report an electrochemical conformation-changing aptasensor with two assay formats: a 30 min assay for routine monitoring and a 5 min assay for rapid emergency testing. To enable “sample-to-answer” testing, a de novo CBZ aptamer (K(d) < 12 nM) with conformational switching due to a G-quadruplex motif was labeled with methylene blue and immobilized on a gold electrode. The electrode fabrication and detection conditions were optimized using electrochemical techniques and visualized by atomic force microscopy (AFM). The aptasensor performance, including reproducibility, stability, and interference, was characterized using electrochemical impedance spectroscopy and voltammetry techniques. The aptasensor exhibited a wide dynamic range in buffer (10 nM to 100 μM) with limits of detection of 1.25 and 1.82 nM for the 5 and 30 min assays, respectively. The clinical applicability is demonstrated by detecting CBZ in finger prick blood samples (<50 μL). The proposed assays provide a promising method to enable point-of-care monitoring for timely personalized CBZ dosing. American Chemical Society 2022-10-17 /pmc/articles/PMC9631757/ /pubmed/36340178 http://dx.doi.org/10.1021/acsomega.2c04865 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Chung, Saeromi
Singh, Naveen K.
Gribkoff, Valentin K.
Hall, Drew A.
Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
title Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
title_full Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
title_fullStr Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
title_full_unstemmed Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
title_short Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
title_sort electrochemical carbamazepine aptasensor for therapeutic drug monitoring at the point of care
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631757/
https://www.ncbi.nlm.nih.gov/pubmed/36340178
http://dx.doi.org/10.1021/acsomega.2c04865
work_keys_str_mv AT chungsaeromi electrochemicalcarbamazepineaptasensorfortherapeuticdrugmonitoringatthepointofcare
AT singhnaveenk electrochemicalcarbamazepineaptasensorfortherapeuticdrugmonitoringatthepointofcare
AT gribkoffvalentink electrochemicalcarbamazepineaptasensorfortherapeuticdrugmonitoringatthepointofcare
AT halldrewa electrochemicalcarbamazepineaptasensorfortherapeuticdrugmonitoringatthepointofcare